A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies
Daiichi Sankyo
Summary
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
Description
DS3790a may be effective in the treatment of patients with hematological malignancies. The primary objective of this study will assess the safety and preliminary efficacy of DS3790a monotherapy and combination regimens.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
To be eligible to participate in this trial, an individual must meet all the following criteria: 1. Sign and date the ICF, prior to the start of any trial-specific procedures. 2. Adults \>=18 years at the time the ICF is signed. 3. History of one of the histologically documented hematologic malignancies according to the 5th edition of WHO classification as specified in the protocol. 4. NHL participants only: Agree to provide baseline tumor tissue samples as specified in the protocol. 5. ECOG PS of 0, 1 or 2 assessed no more than 14 days prior to initiation of trial intervention. 6. Has adequa…
Interventions
- DrugDS3790a
Administered as specified in the protocol
- DrugCombination drug
Administered as specified in the protocol
- DrugCombination drug
Administered as specified in the protocol
Locations (5)
- Research SiteNew York, New York
- Research SiteLille
- Research SiteNagoya
- Research SiteTokyo
- Research SiteTokyo